![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety Analysis of Islatravir in Combination
With Doravirine in Treatment-Naïve Adults
With HIV-1 Infection Through 96 Weeks
|
|
|
IAS: Week 96 Metabolic and Bone Outcomes of a Phase 2b Trial of Islatravir and Doravirine - (07/19/21)
IAS 2021 July 18-22
D. Cunningham,1 J.-M. Molina,2 Y. Yazdanpanah,3 A. Afani Saud,4 C. Chahin Anania,5 S.O. Klopfer,6 A. Grandhi,6 K. Eves,6 D. Hepler,6 C. Hwang,6 R. Lahoulou,7 T.A. Correll6
1Pueblo Family Physicians Ltd, Phoenix, United States, 2Saint-Louis Hospital and University of Paris, Paris, France,
3Bichat Hospital, Paris, France, 4University of Chile, Santiago, Chile, 5Hospital Hernan Henriquez Aravena of Temuco, Temuco, Chile, 6Merck & Co., Inc., Kenilworth, NJ, United States, 7MSD France, Puteaux, France
![0722211](../images/072221/072221-5/0722211.gif)
![0722212](../images/072221/072221-5/0722212.gif)
![0722213](../images/072221/072221-5/0722213.gif)
![0722214](../images/072221/072221-5/0722214.gif)
![0722215](../images/072221/072221-5/0722215.gif)
![0722216](../images/072221/072221-5/0722216.gif)
![0722217](../images/072221/072221-5/0722217.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|